Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AGNPF save search
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 7.95%
H: 45.61%
C: 24.56%
acquisition pharmaceuticals research program
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 3.21%
H: 29.32%
C: -3.11%
study
Algernon Pharmaceuticals Announces Closing of Private Placement
Published: 2023-12-27 (Crawled : 21:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 9.2%
H: 20.51%
C: 15.38%
pharmaceuticals
Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study
Published: 2021-10-08 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -7.45%
H: 16.61%
C: 11.3%
fda phase 2 chronic cough
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
Published: 2024-01-31 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 5.02%
H: 13.06%
C: 11.46%
patent treat pharmaceuticals grant chinese
Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 7.69%
H: 12.89%
C: 7.45%
management
Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
Published: 2023-04-17 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -1.08%
H: 12.66%
C: 4.75%
patent pharmaceuticals application
Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -1.64%
H: 11.67%
C: 8.0%
application australia research
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.9%
H: 11.11%
C: 11.11%
offering pharmaceuticals
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
Published: 2021-12-08 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 3.62%
H: 10.26%
C: 0.87%
phase 2 drug stroke
Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Published: 2022-01-05 (Crawled : 03:00) - algernonpharmaceuticals.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -2.17%
H: 9.52%
C: 9.52%
als stroke
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 1.48%
H: 8.75%
C: 6.25%
fibrosis study phase 2
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -6.89%
H: 7.79%
C: 7.47%
als drug patent intel
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
Published: 2022-02-23 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -2.14%
H: 7.44%
C: 3.51%
als kidney program research disease
Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split
Published: 2023-03-01 (Crawled : 02:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -4.8%
H: 5.88%
C: 1.79%
pharmaceuticals
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
Published: 2021-11-01 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -4.6%
H: 5.49%
C: 4.83%
treatment
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Published: 2022-09-19 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -3.64%
H: 4.85%
C: 4.85%
treatment fda designation
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: 0.37%
H: 4.5%
C: -11.69%
drug stroke pharmaceuticals research program
Algernon Pharmaceuticals Announces Share Consolidation
Published: 2021-11-17 (Crawled : 23:00) - globenewswire.com
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -4.23%
H: 3.41%
C: -19.68%
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
Published: 2022-01-28 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 1.3K
|
Health Technology
|
| O: -0.15%
H: 2.6%
C: -1.72%
als fibrosis application patent
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.73 41.22% 46K
|
n/a
ZCMD | $1.98 36.55% 27M
|
Commercial Services
RWOD | $10.61 32.68% 5.1M
|
n/a
PAPL | $2.07 26.22% 550K
|
AULT | $0.304 25.57% 47M
|
Manufacturing
WISA 4 | $7.19 22.07% 18M
|
Electronic Technology
MCB 4 | $39.53 19.43% 88K
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.